KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Non-Current Deferred Tax Liability: 2013-2025

Historic Non-Current Deferred Tax Liability for Neogenomics (NEO) over the last 12 years, with Sep 2025 value amounting to $20.8 million.

  • Neogenomics' Non-Current Deferred Tax Liability fell 8.45% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $21.5 million for FY2024, which is 81.83% down from last year.
  • Latest data reveals that Neogenomics reported Non-Current Deferred Tax Liability of $20.8 million as of Q3 2025, which was up 4.36% from $20.0 million recorded in Q2 2025.
  • Neogenomics' 5-year Non-Current Deferred Tax Liability high stood at $143.1 million for Q4 2021, and its period low was $1.7 million during Q1 2021.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $23.0 million (2024), whereas its average is $32.4 million.
  • As far as peak fluctuations go, Neogenomics' Non-Current Deferred Tax Liability tumbled by 89.35% in 2021, and later surged by 2,864.97% in 2022.
  • Neogenomics' Non-Current Deferred Tax Liability (Quarterly) stood at $143.1 million in 2021, then decreased by 9.45% to $129.6 million in 2022, then fell by 8.63% to $118.4 million in 2023, then tumbled by 81.83% to $21.5 million in 2024, then declined by 8.45% to $20.8 million in 2025.
  • Its last three reported values are $20.8 million in Q3 2025, $20.0 million for Q2 2025, and $21.0 million during Q1 2025.